OtherBASIC SCIENCE INVESTIGATIONS

Radioimmunotherapy of Head and Neck Cancer Xenografts Using 131I-Labeled Antibody L19-SIP for Selective Targeting of Tumor Vasculature

Bernard M. Tijink, Dario Neri, C. René Leemans, Marianne Budde, Ludger M. Dinkelborg, Marijke Stigter-van Walsum, Luciano Zardi and Guus A.M.S. van Dongen
Journal of Nuclear Medicine July 2006, 47 (7) 1127-1135;

Article Figures & Data

Figures

  • FIGURE 1. 
    FIGURE 1. 

    Immunohistochemical staining of HNSCC xenograft lines FaDu (A and C) and HNX-OE (B and D) with biotinylated L19-SIP (A and B) and cetuximab (C and D) for assessment of ED-B (red staining) and EGFR (staining of cell membrane) expression, respectively.

  • FIGURE 2. 
    FIGURE 2. 

    Biodistribution of intravenously coinjected 125I-L19-SIP (A) and 177Lu-L19-SIP (B) in FaDu xenograft–bearing nude mice at 3, 6, 24, 48, 72, and 144 h after injection.

  • FIGURE 3. 
    FIGURE 3. 

    Biodistribution of intravenously injected 131I-L19-SIP in FaDu xenograft–bearing nude mice at 24, 48, and 72 h after injection.

  • FIGURE 4. 
    FIGURE 4. 

    Biodistribution of intravenously injected 131I-L19-SIP in HNX-OE xenograft–bearing nude mice at 24, 48, and 72 h after injection.

  • FIGURE 5. 
    FIGURE 5. 

    Mean body weights of FaDu xenograft–bearing nude mice intraperitoneally injected with diluent or increasing doses of 131I-L19-SIP. Values are the mean of 5 mice. SDs have been omitted but were <5%.

  • FIGURE 6. 
    FIGURE 6. 

    Mean tumor volume (A) and survival (B) of FaDu xenograft–bearing nude mice after intraperitoneal injection of 131I-L19-SIP (RIT) at day 0, cetuximab (1 mg given 2 times a week intraperitoneally for 4 wk), or both. SDs have been omitted for sake of clarity.

  • FIGURE 7. 
    FIGURE 7. 

    Mean tumor volume (A) and survival (B) of HNX-OE xenograft–bearing nude mice intraperitoneally injected with 131I-L19-SIP (RIT), cetuximab (1 mg given 2 times a week intraperitoneally for 4 wk), or both. SDs have been omitted for sake of clarity.

Tables

  • TABLE 1

    Tumor-to-Tissue Ratios ± SD of Intravenously Injected 131I-L19-SIP in FaDu and HNX-OE Xenograft–Bearing Nude Mice at 24, 48, and 72 Hours After Injection

    24 h48 h72 h
    RatioFaDuHNX-OEFaDuHNX-OEFaDuHNX-OE
    Tumor/blood4.4 ± 1.83.1 ± 1.27.4 ± 3.76.3 ± 1.621.4 ± 1.715.1 ± 1.5
    Tumor/tongue3.4 ± 1.22.1 ± 0.64.7 ± 1.73.6 ± 1.19.3 ± 0.95.5 ± 1.6
    Tumor/sternum9.1 ± 3.78.2 ± 4.59.2 ± 3.28.3 ± 1.516.7 ± 1.314.1 ± 3.1
    Tumor/heart8.1 ± 3.66.0 ± 2.412.6 ± 6.711.5 ± 1.731.0 ± 3.222.7 ± 3.7
    Tumor/lung3.4 ± 1.72.8 ± 0.65.0 ± 1.34.7 ± 0.910.1 ± 3.59.9 ± 2.1
    Tumor/liver14.9 ± 6.810.7 ± 4.520.0 ± 10.318.1 ± 4.850.6 ± 5.638.4 ± 7.9
    Tumor/spleen11.3 ± 5.76.6 ± 2.014.2 ± 7.510.8 ± 1.831.4 ± 1.222.0 ± 5.1
    Tumor/kidney5.6 ± 2.73.9 ± 1.27.5 ± 2.97.2 ± 0.720.2 ± 3.314.2 ± 2.5
    Tumor/bladder2.3 ± 1.11.8 ± 0.21.6 ± 0.51.8 ± 0.52.8 ± 0.52.8 ± 0.5
    Tumor/muscle17.9 ± 6.411.9 ± 3.723.3 ± 9.722.4 ± 3.168.1 ± 15.547.5 ± 2.5
    Tumor/colon4.0 ± 0.92.6 ± 0.63.9 ± 1.22.7 ± 0.24.4 ± 0.94.6 ± 0.3
    Tumor/ileum4.2 ± 1.32.9 ± 0.64.1 ± 1.23.6 ± 0.48.5 ± 5.47.1 ± 1.8
    Tumor/stomach2.6 ± 1.51.7 ± 1.12.9 ± 2.23.1 ± 1.08.8 ± 1.86.3 ± 1.7
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Bookmark this article

Jump to section

Related Articles

Cited By...

More in this TOC Section

Similar Articles